Tel: +49 6172 686-0
About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
8 articles with Fresenius Kabi
Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to the ruling by the Delaware Chancery Court on the complaint filed by Akorn against Fresenius Kabi AG
Although Hurricane Florence has been downgraded to a Category 2, the massive storm has the potential to dump enough rain to produce catastrophic flooding across the Carolinas. Despite the downgrade, Pfizer is taking no chances and will close its North Carolina injectables plant ahead of the storm.
Fresenius Kabi announced today it has introduced four new presentations of Heparin Sodium in the company’s proprietary ready-to-administer freeflex® containers.
Fresenius Kabi now offers 0.2 mg per mL, 0.4 mg per 2 mL, 1 mg per 5 mL, and 4 mg per 20 mL presentations
Fresenius Kabi Introduces Adenosine Injection, USP in 60 mg per 20 mL and 90 mg per 30 mL Presentations
Complete portfolio of all commonly used sizes and strengths of Adenosine Injection, USP now available from Fresenius Kabi
Almost one year to the day after Fresenius plunked down $4.3 billion to acquire Illinois-based Akorn Pharmaceuticals, the German company announced it was walking away from the deal.
Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement
Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement:
Fresenius Kabi announced today it has received FDA approval for Daptomycin for Injection and the product is available immediately for customers in the United States